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Abstract The cancer stem cell (CSC) model has recently
been approached also in renal cell carcinoma (RCC). A few
populations of putative renal tumor-initiating cells (TICs)
were identified, but they are indifferently understood; howev-
er, the first and most thoroughly investigated are CD105-
positive CSCs. The article presents a detailed comparison of
all renal CSC-like populations identified by now as well as
their presumable origin. Hypoxic activation of hypoxia-
inducible factors (HIFs) contributes to tumor aggressiveness
by multiple molecular pathways, including the governance of
immature stem cell-like phenotype and related epithelial-to-
mesenchymal transition (EMT)/de-differentiation, and, as a
result, poor prognosis. Due to intrinsic von Hippel-Lindau
protein (pVHL) loss of function, clear-cell RCC (ccRCC)
develops unique pathological intra-cellular pseudo-hypoxic
phenotype with a constant HIF activation, regardless of oxy-
gen level. Despite satisfactory evidence concerning pseudo-
hypoxia importance in RCC biology, its influence on putative
renal CSC-like largely remains unknown. Thus, the article dis-
cusses a current knowledge of HIF-1α/2α signaling pathways in
the promotion of undifferentiated tumor phenotype in general,
including some experimental findings specific for pseudo-
hypoxic ccRCC,mostly dependent fromHIF-2α oncogenic func-
tions. Existing gaps in understanding both putative renal CSCs
and their potential connection with hypoxia need to be filled in
order to propose breakthrough strategies for RCC treatment.
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Introduction
According to Cancer Statistics, 2015, RCC will be responsi-
ble for 5 % of all malignancies in men and 4 % in women in
the USA. RCC is characterized by a high index of advanced
stages at diagnosis (17 % for regional/locally advanced and
16% for metastatic stage) and a high mortality (5-year surviv-
al rate for metastatic disease of only 12 %) [1]. In addition,
tumor recurrence occurs in 40 % of patients after curative
surgical resection. Moreover, RCC is resistant to chemother-
apy and radiation, and weakly sensitive to immunotherapeutic
agents such as INF-α and IL-12. But in recent years, the dis-
covery of new molecular and cytogenetic markers has led to
the recognition and classification of several novel subtypes of
RCC [2] and to the introduction of targeted therapies for met-
astatic stage RCC, including RTK and mTOR kinase inhibi-
tors [2, 3]. However, complete responses are rare, thus, RCC
is still a tumor of unpredictable presentation and poor progno-
sis [3]. Therefore, future studies have to provide more infor-
mation concerning molecular and cellular mechanisms under-
lying RCC development and resistance to targeted therapies.
RCC denotes a set of cancers with diverse genetic and
histopathological features, clinical course, and response to
therapy. RCC is considered to originate from the highly
heterogeneous renal tubular epithelium. Depending on a
specific microanatomical site of malignant transformation,
a resulting tumor displays unique characteristics, allowing
for relatively straightforward identification in most cases
[4, 5]. In the Heidelberg classification, ccRCC is the most
common histological subtype of RCC [2]. According to
the long-standing clonal evolution model, a recent break-
through multiregional genetic analysis of four RCCs pro-
vided evidence of intra-tumor heterogeneity in each tumor,
with spatially separated heterogeneous somatic mutations
and chromosomal abnormalities (allelic imbalances and
ploidy aberrations), that supplies evolutionary reservoir of
phenotypic tumor cell diversity through Darwinian selec-
tion, predicting therapeutic failure due to adapted aggres-
sive drug-resistant clones of malignant cells. In addition, a
single tumor-biopsy specimen was found to contain a non-
representative minority of genetic aberrations that are pres-
ent in an entire tumor, therefore, intra-tumor heterogeneity
may explain difficulties in the validation of molecular bio-
markers essential in personalized oncology [6]. The novel
CSC or TIC or TPC model introduces an additional ex-
planation, suggesting that intra-tumor heterogeneity may
also result from functional diversity among cancer cells
in different states of aberrant differentiation [7, 8]. Al-
though two essential paradigms of cancer propagation –
the clonal evolution and CSC model – were originally
presented as mutually exclusive theories of intra-tumor
heterogeneity, they can be easily reconciled and are both
an integral part of cancer development and evolution,
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because in the context of the clonal evolution concept,
altered tumor cells with stem cell-like characteristics may
well be important units of selection [7–13]. CSCs are
characterized by an extraordinary capacity for tumor initi-
ation and maintenance due to unlimited self-renewal and
multilineage differentiation (multipotency) towards hetero-
geneous progeny. Possible analogies with normal
stem/progenitor cells are still being investigated [8–11].
Following a developmentally hierarchical concept of tumor
generation resulting from genetic and/or epigenetic alterations
of a very small compartment of normal adult somatic tissue-
resident stem/progenitor cells, as described in a number of
solid malignancies (breast [14], brain [15], colorectal [16],
pancreatic [17], hepatic [18], lung [19], prostate [20], ovarian
[21], endometrial cancer [22], malignant melanoma [23], and
others), only a few diverse studies, reviewed in chapter 2 and
Table 1, have focused on the identification of putativeCSCs in
RCC. These experimental results indicate that different cell
subpopulations with stem cell-like properties may be present
within this heterogeneous and aggressive tumor. No generally
applicable markers are known so far, thus, characterization of
putative renal CSCs is mainly based on functional studies.
What is important, scientists should be aware of the existence
of potential multiple, unappreciated and largely unavoidable
observational errors in methodology used to study renal TICs.
In view of these previously unexplored methodological
biases, re-examination of the CSC hypothesis in other solid
tumors is probably warranted [24].
Hypoxia, through the activation of HIFs, leads to adaptive
changes within a cancer cell, followed by aggressive behavior
which contributes to tumor progression and treatment resis-
tance, and, as a consequence, determines an unfavorable prog-
nosis. The correlation of intra-tumor hypoxia with a poor prog-
nosis might be related to the increase in immature, highly ag-
gressive and therapy-resistant malignant cells with stem cell-
like characteristics [25–29]. Data reviewed in chapter 3 show
this phenomenon for a number of solid tumors, both cell lines
and cells directly obtained from patient-derived specimens, but
the exact role played by hypoxia in CSC-like phenotype pro-
motion began to be appreciated scarcely a few years ago and is
still not fully known. In view of its unique pathological intra-
cellular pseudo-hypoxic (mimicking hypoxia) phenotype due
to a biallelic loss of pVHL function in the absolute majority of
clinical cases, with a constitutive HIF-overactivation even in
normoxic conditions [2], ccRCC appears as one of the most
malignant solid tumors. The exact role of hypoxia in the gov-
ernance of individual identified putative renal CSC populations
was not studied, despite quite substantial knowledge
concerning HIF activity, especially HIF-2α oncogenic actions,
in RCC development and progression. There are also a few
findings documenting the hypoxic-induction of HIF-1α-depen-
dent, de-differentiation- and metastasis-associated EMT in
RCC. Finally, some putative renal CSC markers are activated
by hypoxia and possibly contribute to tumor aggressiveness
and stem cell functions (see chapter 3 and Fig. 3).
In conclusion, the review analyzes the existing data from
both a growing field of CSCs and hypoxia, with the emphasis
on the most recent studies, and tries to provide a potential,
preliminary link between the pseudo-hypoxic and immature
CSC-like phenotype in RCC (see Fig. 2). Filling gaps in un-
derstanding this indifferently studied relationship in RCC is
necessary to overcome current treatment limitations by trans-
lation of novel discoveries into selective and efficient break-
through therapies significantly improving prognosis.
The CSC Model in RCC
CD133+ Renal Adult Progenitor Cells
CD133 (prominin-1) is a marker commonly used to define
CSC populations. It is a five transmembrane domain-glyco-
protein, in human first isolated from HSCs, expressed on var-
ious types of stem/progenitor cells and differentiated cells, but
its biological function is still ambiguous [30]. Two glycosyl-
ated renal stem/progenitor cell-associated CD133 epitopes are
recognized by monoclonal antibodies – CD133/1 (clone
AC133) and CD133/2 (clone 293C3) [31]. Upon CSC differ-
entiation, the AC133-specific epitope, but not the entire
CD133 protein, is lost [32]. Prominin-1 was investigated as
a marker for identification of renal TICs. A very rare popula-
tion (less than 1 % of total tumor cells) of CD133+/CD34−
cells was found in human RCC using magnetic bead separa-
tion [33]. This population expressed surface markers typical
for MSCs [34], such as CD29, CD44 and CD73, the meso-
dermal marker vimentin, and the embryonic kidney develop-
mental stem cell marker Pax-2 which suggests renal origin.
Moreover, CD133+ cells could undergo epithelial and endo-
thelial differentiation both in vitro and in vivo. However, they
were not able to form carcinomas after subcutaneous injection
into SCIDmice, indicating no tumorigenic potential [33]. This
result is in contrast with the idea that, as in the case of CSCs
derived from other organs, RCC CSCs arise from renal pro-
genitors expressing the CD133 marker [35]. Because of the
potential of CD133+ cells for in vivo endothelial differentia-
tion in SCID mice, they were suggested to play a pivotal role
in tumor vasculogenesis. First, these cells, cultured in the
presence of tumor supernatant, differentiated into endothelial
cells, suggesting that the tumor microenvironment could be
involved in their endothelial commitment. Furthermore,
CD133+ cells, when co-transplanted with cancer cells at the
same ratio as in RCC, significantly enhanced tumor engraft-
ment, growth and vascularization – probably by the produc-
tion of cancer progression-favoring growth factors [33]. This
phenomenon cannot be linked to the cancerous nature of
tumor-derived CD133+ cells, because the same results were
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Table 1 In vitro and in vivo properties of various putative CSC-like subpopulations identified within RCC of adults
Identification method Markers Functional analyses
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in vitro
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in vitro
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+ ND ND ND ND ND ND ND + ND ND ND
ND not determined
1A major subpopulation within CXCR-4+ sphere cells derived only from established cell line SK-RC-17, not from primary cell lines
2 The CD44 and CD29 MSC markers (however, no significant difference compared to non-SP cells)
3 Significantly higher cell number in SP than in non-SP cells, however, lower cell number than in the SP of the normal kidney
4 The CD44 MSC marker, along with CD24 (however, no significant difference compared to non-sphere cells)
5 Expressed on nearly all non-sphere cells, however, significantly reduced expression on sphere-forming cells
6 No significant difference compared to non-sphere cells
7 The CD44 MSC marker, along with CD24
8 The CD44 MSC marker
9 Significantly higher ALDH activity in SP than in non-SP cells only in the case of ACHN cell line (ALDH+ SPACHN CSCs)
10 The CD90 MSC marker (however, no significant difference compared to non-SP cells)
922 Stem Cell Rev and Rep (2015) 11:919–943
obtained with normal human renal tubular CD133+ progeni-
tors [36]. In addition, CD133+ RCC cells exhibited the same
progenitor phenotype as their normal counterparts, thus, they
may represent tumor-infiltrating residents of the normal adult
kidney [33]. Normal adult multipotent CD133+/CD24+ pro-
genitor cell subpopulations were isolated from both tubular
epithelium [36–38] and parietal glomerular epithelium of the
Bowman’s capsule [38–40] within the renal cortex, whereas in
the inner medulla they were detectable in the Henle’s loop and
its thin limb segments [41]. Embryonic multipotent CD133+/
CD24+ renal progenitors were also identified [42, 43]. Geno-
mic analysis of normal renal tubular and glomerular
multipotent CD133+/CD24+ progenitor cells revealed no sig-
nificant differences in gene expression patterns which con-
firms genetic homogeneity [38].
To sum up, CD133+ cells, isolated from RCC, seem to be
non-tumorigenic and represent resident adult kidney progeni-
tors which may differentiate into endothelial cells forming
new blood vessels in vivo in SCID mice, supporting tumor
development [33]. However, a precise function of CD133+
progenitors in renal carcinogenesis requires more studies.
Putative Renal CSCs
CD105 (endoglin), a surface transmembrane molecule, acts as
a part of the receptor for TGF-β1/3, a pleiotropic cytokine
regulating different cellular functions including proliferation,
differentiation and migration. Endoglin is a hypoxia-inducible
protein expressed abundantly by angiogenic endothelial cells,
therefore, it is speculated to be involved in hypoxia-initiated
neo-vascularization [44–46]. Bussolati et al. [47] isolated a
subpopulation of putative TICs using CD105 magnetic cell
sorting of renal carcinomas, independently from a histologic
type of origin. In addition, CD105+ TICs were found in
rhabdoid meningioma [48] and osteosarcoma (the CD44+/
Stro-1+/CD105+ population) [49]. CD105+ TICs, isolated by
Bussolati et al., represented less than 10 % of the tumor. The
phenotype of in vitro analyzed CD105+ cells revealed several
stem cell properties: expression of a set of MSCmarkers, such
as CD44, CD90, CD146, CD73, CD29, and the mesodermal
marker vimentin; expression of embryonic stem cell markers,
such as Nanog, Oct4, Musashi, Nestin, renal Pax-2, and con-
current lack of differentiative epithelial proteins such as CK;
growth in non-adhesive spheres; clonogenic ability; self-
renewal ability; differentiation potency (in differentiating con-
ditions) into tumor components carrying specific
differentiative epithelial and endothelial markers and lack of
stem cell antigens. A low number of CD105+ cell clones were
able to generate serially transplantable carcinomas in SCID
mice containing a small fraction of the undifferentiated
CD105+ tumorigenic cell population and a lot of differentiated
CD105− cells. CD105− cells did not induce tumors, indicating
the tumor propagating potential of CD105+ cells. CD105+
clones, originating from transplanted tumors, displayed the
same phenotype as primary clones. Re-established RCCs re-
capitulated the histological pattern of the heterogeneous tumor
of origin, reflecting the differentiation capability of CD105+
cells. Evidence of in vivo endothelial differentiation of
CD105+ clones was confirmed by the human origin of blood
vessels after RCC xenotransplantation. On the basis of this,
renal TICs are thought to contribute to intra-tumor vasculari-
zation [47], therefore, angiogenesis in RCCmight be support-
ed not only by endothelial cells recruited from adjacent vessels
or circulating CD133+ progenitors [33]. In vivo endothelial
differentiationwas also shown for TICs derived from glioblas-
toma [50] as well as hepatocellular [51], ovarian [52] and
breast carcinoma [53], and seems to be rather a general phe-
nomenon of these cells [35]. It should be noted that in vivo
differentiation of TICs into endothelial cells suggests a com-
plex connection between tumor and its microenvironment.
Emerging evidence indicates that TICs coordinate tumor pro-
motion (growth, angiogenesis, metastatic diffusion) through
their interactions with niche by two-directional release of
some extracellular factors – providing TIC maintenance on
the one hand, and tumor progression on the other. Besides
soluble factors, tumor MVs (exosomes) emerged as potential
candidates for cell-to-cell communication. MVs may repro-
gram target cells by transferring various bioactive molecules
and initiating epigenetic changes, including membrane recep-
tors, proteins, lipids and RNAs [3]. MVs released from
CD105+ RCC cells promoted in vitro and in vivo tumor an-
giogenesis – probably by carrying pro-angiogenic mRNAs
and miRNAs that were absent in those derived from
CD105− differentiated tumor cells. Additionally, MVs favored
lung metastases by inducing lung local expression of pre-
metastatic niche formation enhancing factors [54]. In subse-
quent research, CD105+CSC-derived MVs promoted persis-
tent phenotypical changes in mesenchymal stromal cells
supporting tumor progression in vitro (migration, matrix re-
modeling, angiogenesis and production of growth-stimulating
cytokines) and in vivo (proliferation and vascularization) [55].
Gassenmaier et al. [56] used a novel approach to identify
putative CSC markers in RCC by comparing expression of a
number of candidate cell surface proteins in two primary cell
lines derived from two tumors with different aggressiveness –
a slowly progressing localized and rapidly progressing meta-
static stage disease. This was reflected by long and short sur-
vival of patients, respectively, as well as by different tumori-
genic potential in immunocompromised mice and sphere-
forming capacity of analyzed cell lines, suggesting differences
in the content of TICs. CXCR-4 was found to be the most
reliable CSC marker. A CSC-like subpopulation expressing
CXCR-4 was presented at a higher level (5 % comparing to
0.8%) in the more aggressive cell line (ametastatic stage), and
enriched in tumor spheres derived from both primary cell lines
and one established cell line SK-RC-17. CXCR-4+CSCs vs.
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CXCR-4− cells had a stronger sphere-forming ability and tu-
morigenicity. Compared to adherently grown cells, CXCR-
4+CSCs from derived spheres expressed stemness proteins
(Oct4, Sox2 and Nanog) at elevated levels, had a reduced level
of epithelial CK (more immature mesenchymal phenotype),
and were more resistant to anti-angiogenic RTK inhibitors
Sunitinib, Sorafenib and Pazopanib. Being considered to drive
RCC progression and metastasis, a high content of CXCR-
4+CSCs, estimated by the amount of CXCR-4 expression, cor-
related with a worse prognosis (strong prognostic power for
patients without metastases at the time of diagnosis). Impor-
tantly, CXCR-4 function was needed for maintenance of this
CSC population (sphere-forming capacity). The above data
may suggest that highly tumorigenic CXCR-4+ cells residing
within both primary RCC cell lines represent the CSC-like
population. In contrast to results from Bussolati et al. [47],
the CD105 marker was only marginally co-expressed in the
CXCR-4+ cell population in spheres from both primary cell
lines. However, CD105+ cells represented a major subpopula-
tion within CXCR-4+ sphere cells derived from established
RCC cell line SK-RC-17. This may indicate that CD105 is not
essential for RCC initiation or marks a rare, highly tumorigen-
ic subpopulation of putative renal CSCs only in some primary
tumors or established cell lines, thus, is not suitable for the
identification of CSCs in each experimental approach. On the
other hand, expression of CD133 was restricted to a small
fraction of cells which number did not increase with tumor
sphere formation [56].
In addition, Nishizawa et al. [57], using two RCC cell lines,
demonstrated that the overexpression of the HSP40 family
member, DNAJB8, increased the percentage of SP cells and
enhanced their tumor-initiating ability. Conversely, DNAJB8
attenuation declined the percentage of SP cells and reduced
tumorigenicity. This observation indicates that DNAJB8 con-
tributes to CSC-like phenotype of RCC and appears as a new
antigen of renal CSCs.
As the identification of CSC selective markers is not al-
ways easy, the culture system could be useful for functional
selection and enrichment of TICs by exploiting their ability to
generate spheres [3]. Cells growing in suspension as tumor
spheres in serum-free medium, supplemented with growth
factors, were isolated from SK-RC-42 RCC cell line by Zhong
et al. [58]. The sphere-forming population showed the
stemness potential of CSCs, in contrast to monolayer adherent
cells – higher in vitro levels of several stem cell markers
(Oct4, Nanog,β-catenin, BMI), ability for self-renewal, stron-
ger tumorigenicity, and resistance to chemotherapeutic agents
and irradiation. Furthermore, the immunophenotype of
sphere-forming renal CSCs suggests that they may play an
important role in the evasion of tumor growth from immune
surveillance. In contrast, no significant differences were found
between monolayer adherent and sphere-forming cells for ex-
pression of CD44, CD24 and CD133 markers. Surprisingly,
the CD105 marker was expressed on nearly all non-sphere
cells, but its expression on sphere cells was significantly re-
duced. Therefore, data obtained in this study do not definitive-
ly address the issue of a relative frequency ofCSCs in SK-RC-
42 sphere-forming and monolayer adherent cells. In addition,
Lichner et al. [59] isolated RCC spheres exhibiting CSC-like
properties coupled to TGF-β-EMT axis, including
clonogenicity, self-renewal capacity, tumorigenicity, the abil-
ity to differentiate to cell types of the tumor of origin as well as
increased expression of stem cell-related transcription factors
(Oct4, Nanog, Klf4 and LIN28).
Another functional approach of renal CSC isolation was
performed by the identification of cells appearing as the SP
[60] from both normal and malignant tubular epithelial cells of
the nephron, using cytofluorimetric evaluation of Hoechst
33342 dye uptake [61]. This efflux assay, first developed in
the hematopoietic system, allows for the selection of a cell
population that rapidly extrudes dyes due to specific mem-
brane transporters typically associated with stemness [62].
Addla et al. [61] demonstrated about 4 % of normal kidney
cells and about 6 % of RCC cells could be defined as the SP.
The SP of RCC exhibited in vitro sphere-forming capacity and
enhanced proliferative potential as well as expressed more
widelyβ-catenin, Notch, Sonic Hedgehog and Pax-2 stem cell
markers, as compared to non-SP RCC cells. However, RCC
SP cells were noted both in G1 (most of cells) and G0
(quiescent) phase, indicating heterogeneity of this population
and suggesting that the terms SP and CSC perhaps cannot be
used interchangeably, but further studies are needed. Indeed,
researchers still question the full relationship between SP cells
and CSC-like phenotype [60]. For example, the SP of glio-
blastoma multiforme does not necessarily contribute to self-
renewal and tumorigenicity related to CSCs [63]. These ques-
tionable interpretations suggest that the reliability and repro-
ducibility of the SP assay regarding to CSCs are the challenge
and should be improved [64]. Differential expression of the
CD133 marker between the SP of the normal kidney and RCC
was found (15 and 3 %, respectively) [61]. The SP of the
normal kidney expressed the same markers as identified in
renal CD133+ progenitors by Bussolati et al. [36]. According
to the RCC SP, above-mentioned results were confirmed in
subsequent research of this group [65]. In addition, Huang
et al. [66] identified SP cells of 769P RCC cell line (4.8 %).
The 769P SP cell fraction possessed the CSC-like character-
istics, including the ability for increased proliferation, self-
renewal and differentiation as well as strong resistance to che-
motherapy (related to the ABCB1 transporter) and radiother-
apy. Moreover, Lu et al. [67] identified two SP cell subpopu-
lations within cultured 786-O RCC cell line – Rh123high and
Rh123low. Rh123high cells were the minority among 786-O
cells, exhibited a noticeably higher proliferative activity,
long-term differentiation potential and resistance to radiation
as well as enhanced colony-forming efficiency and
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tumorigenic potential, compared to Rh123low cells, thus, may
be regarded as a novel CSC-like cell population of RCC.
However, CD105 marker expression was not observed on
the surface of 786-O cells. Furthermore, the characterization
of RCC SP cells with the high brilliance synchrotron-FTIR
spectroscopy revealed the presence of their various subpopu-
lations with diverse biochemistry, but there is neither evidence
of a differential role of particular subpopulations in carcino-
genesis, nor were any specific set of markers identified [68].
Based on the utility of high ALDH enzymatic activity for
the functional identification of CSCs [69], Debeb et al. [70]
studied cancer cells with stem-cell like features belonging to
the HEK 293 T population. HEK 293 T cells, cultured in vitro
as 3D spheres in serum-free stem cell-promoting culture con-
ditions, exhibited CSC-like phenotype – they contained the
larger CD44+/CD24−/ALDH+ cell population compared to
cultured monolayer cells, displayed upregulated stem cell sur-
vival signaling, including β-catenin, Notch and survivin, had
increased expression of several mesenchymal, pro-metastatic
EMT-related genes, and were radiation-resistant. Serial xeno-
grafts of HEK 293 T cells into immunocompromised mice
yielded aggressive, self-renewing tumors. These findings sug-
gest that HEK 293 T is a valuable cell line to study the plas-
ticity of transformed embryonic cells, thus, representing an
important research tool for studying molecular mechanisms
in putative renal CSC maintenance. Strongly tumorigenic re-
nal ALDH+CSC-like cells were also identified by Wang et al.
[71] by the use of the xenograft model of ACHN (pleural
effusion metastasis) and Caki-2 RCC cell lines. Isolated cells
displayed several stem cell-like properties in vitro, including
clonogenic and self-renewal ability, and increased expression
of Oct3/4A, Nanog and Pax-2 stem cell markers. In vivo ex-
periments showed that cells with a high ALDH activity had
greater tumorigenicity compared to their counterparts with a
low ALDH activity, generating new tumors with as few as 25
cells. In addition, Ueda et al. [72] used the combination of two
functional approaches, the SP approach and ALDH enzymatic
approach, to identify the CSC-like population residing within
ACHN and KRC/Y RCC cell lines. SP fractions in ACHN
and KRC/Y were 1.4 and 1.7 %, respectively. ACHN SP cells
revealed a significantly stronger ALDH activity than non-SP
cells (about 33 % and about 15 %, respectively). ALDH+
ACHN cells had a stronger sphere-forming and self-renewal
ability as well as showed enhanced expression of CSC-related
genes (stemness, drug efflux transporter, anti-apoptotic, angio-
genic and EMT-related genes) and higher tumorigenic poten-
tial in SCIDmice compared to non-SP cells with lower ALDH
activity. Importantly, whereas ACHNSP cells showed a stron-
ger sphere-forming ability and drug resistance (INF-α) com-
pared to non-SP cells, the tumorigenic ability was only slight-
ly higher, suggesting that only ALDH+ cells within the SP
population rather than all SP cells possess real CSC-like prop-
erties. In the second cell line analyzed, KRC/Y, there was no
difference in ALDH expression between SP and non-SP cells.
Intriguingly, this study found that while SP cells of KRC/Y
cell line contained about five times more CD105+ cells than
non-SP cells, there were no differences in CSC-like properties
between SP and non-SP cells, therefore, KRC/Y SP cells lack
this characteristics. In turn, within more aggressive ACHN
cell line, the CD105 marker was expressed only in a few cells.
Thus, these results are in conflict with the findings of
Bussolati et al. [47], regarding the CD105+CSC population,
and suggest that CD105 may not be a universal CSC-related
marker of RCC.
Furthermore, recent studies in pediatric kidney cancer,
Wilms’ tumor (nephroblastoma), point to an embryonic renal
stem/progenitor initiating cell that fails to differentiate proper-
ly and undergoes malignant transformation to a NCAM1+/
ALDH+CSC [73].
Taken together, although CD105+ cells are the most thor-
oughly studied CSC population of RCC [47, 54, 55], CD105
may not necessarily be a universal marker of renal TICs [56,
58, 67, 72].
Putative Origin of Renal CSCs
The origin of putative renal CSCs is still unknown, because to
date experimental data seem to be incomplete and discordant.
All efforts to isolate and characterize resident renal
stem/progenitor cells suffer from numerous technical limita-
tions, being only inferred from some similarities of cell-
surface markers which is not always unequivocal [4, 74, 75].
Considering a high complexity of the adult kidney, this organ
is likely to harbor various stem/progenitor cell pools with
restricted differentiation ability which might be involved in
the regeneration of different tissue regions after injury [4].
Over the past few years, several populations of resident
multipotent stem cells with mesenchymal characteristics were
identified particularly in tubular and glomerular components
of the nephron from the adult [76] and embryonic human [77],
and rodent kidney [75, 78–81], indicating that renal stem cells
may exist. Bruno et al. [76] sorted adult CD146+ stem cells
from human glomeruli deprived of the Bowman’s capsule,
that were positive for MSC surface markers (including
CD105), the mesodermal marker vimentin and embryonic
stem cell markers (Nanog, Oct4, Musashi, Nestin), and nega-
tive for the renal progenitor-specific CD133 marker, epithelial
markers (CK and E-cadherin) as well as for hematopoietic
(CD45 and CD34) and endothelial (CD31) markers.
CD146+ MSCs exhibited in vitro capability for clonogenicity,
self-renewal and multipotency/bipotency (epithelial and endo-
thelial differentiation). Expression of the renal Pax-2 marker
suggests that these cells are a tissue-resident population.
In RCC, tumorigenic multipotent/bipotent CSC-like
CD105+ cells lack expression of CD133 and CD24
markers [47], while they are present in normal adult and
Stem Cell Rev and Rep (2015) 11:919–943 925
embryonic renal epithelial [36–43] as well as in corre-
sponding non-tumorigenic tumor-derived CD105− progeni-
tor cells [33]. Thus, it is suggested that putative renal
CSCs do not originate from CD133+ renal progenitors,
but rather from a yet undefined, undifferentiated kidney-
resident adult CD105+ stem cell population retaining mes-
enchymal phenotype, possibly that studied by Bruno et al.
[76]. This is in contrast with the idea of RCC originating
from CD133+ cells, as in other tumors [30]. Alternatively,
CD133+ cells are very few in the non-SP population of
normal kidney as well as in SP and non-SP RCC cells,
compared to the SP of the normal kidney (however,
CD133 was not present on presumable normal kidney
stem cells, isolated by Bruno et al. [76]), pointing the loss
of the CD133 marker which could be a very early event
in stem cell differentiation and possibly in malignant trans-
formation. This finding is also in opposition to the com-
mon notion that CD133 is a definitive stem cell marker in
solid tumors [61]. In line with this, another well described
putative renal CSC population, CXCR-4+, did not express
CD133 [56] as well as marker expression on sphere-
forming cells vs. adherent cells was not specific [58].
Moreover, CD133 expression was evaluated on samples
of human RCC, using the stem cell-specific anti-human-
CD133/1 (AC133) monoclonal antibody recognizing the
glycosylation-dependent epitope of prominin-1, but no cor-
relation with pathological changes and affected patient
prognosis was found [82]. Additionally, an immunohisto-
chemical study of highly differentiated, non-metastatic and
Oct4-negative ccRCC revealed high CD133 expression,
suggesting that it is a favorable prognostic marker [83].
In contrast to above-mentioned results, a stable transfec-
tion of CD133 into HEK293 cells induced their in vivo
tumor-initiating properties [84]. In this scenario,
Galleggiante et al. [85] has recently described a ccRCC-
derived CD133+/CD24+/CTR2+ cell population. It showed
some stem cell-like properties similar to those of CD133+/
CD24+ tubular progenitors from the healthy kidney, in-
cluding in vitro self-renewal and multipotency, and
in vivo angiogenic potential, but no expression of MSC
markers. Comparing to their non-neoplastic counterparts,
CD133+/CD24+/CTR2+ cells could regenerate tumor
in vitro in soft agar (small colonies), were more undiffer-
entiated (expressed higher embryonic stem cell marker
levels), and had an individual gene expression profile, in
particular, CTR2 was identified as a cell membrane pro-
tein involved in cisplatin chemoresistance that could be
used to discriminate this population from normal progeni-
tors. Furthermore, a very recent study of Varna et al. [86]
indicated the enrichment of tumorigenic CD133/CXCR-4-
co-expressing cells, considered CSCs by the authors, in
perinecrotic vs. perivascular areas of primary metastatic
RCCs and their xenografts.
In the kidney, which has lower cell turnover compared to
highly proliferating organs such as the gastrointestinal tract
and skin [4, 35], the evaluation of putative stem cells is fas-
tidious and their role in tissue repair is less evident. It is im-
portant to note that the CSC theory is mainly based on func-
tional approaches. As a result, TICs do not necessarily have to
be derived from normal tissue stem cells [4]. Alternatively, it
could be postulated that kidney tissue lacks a true stem cell
compartment [35]. First, renal tubular cells may be suggested
to modulate their phenotype towards stemness in response to
microenvironmental stimuli due to plastic cell phenotype ev-
idenced by staying in G1 phase of the cell cycle (cyclin D1
activity) [87]. In addition, renal tubular epithelium is almost
entirely quiescent in the basal state [88], but displays a con-
siderable proliferative/regenerative capacity upon acute renal
injury. This step does not involve specialized progenitors or a
stem cell pool, but instead requires randomly surviving, ter-
minally differentiated tubular epithelial cells [87, 89–91].
Thus, a mechanism of renal CSC generation, different from
genetic and/or epigenetic alterations of kidney-resident stem
cells, might theoretically occur, implying the de-
differentiation process of mature tubular epithelial cells to-
wards immature phenotype [4, 35]. Indeed, terminally differ-
entiated tubular cells were shown to de-differentiate through
the EMT process and actively proliferate during tubular repair
[92, 93]. In breast cancer cells, the inhibition of E-cadherin, a
marker strongly associated with epithelial phenotype, was
demonstrated to induce mesenchymal traits and enhance
self-renewal ability [94]. During regeneration, tubular re-
expression of the kidney-specific marker Pax-2 supports a
de-differentiation concept [95]. These observations could
serve as the bridge between two models of cancer evolution
in RCC – the clonal evolution and CSCmodel – since the de-
differentiation process may occur at various stages of malig-
nant transformation (selection of aggressive cancer cell
clones) [4]. Taking into consideration a high heterogeneity
of epithelial structure and a diverse differentiation state of
malignant renal convoluted tubular cells – from stem to ma-
ture, through progenitor cells, the resulting renal CSCs could
display variable, stem cell-like properties and malignancy, de-
pending on which cell type underwent neoplastic transforma-
tion [4, 35].
Kidney-homing bone marrow-derived MSCs could be in-
volved in renal repair as an alternative mechanism to resident
stem/progenitor cells with mesenchymal characteristics – ei-
ther through direct engraftment into injured kidney or
paracrine/endocrine signaling, including mitogenic, anti-apo-
ptotic, anti-inflammatory and pro-angiogenic effects [74, 77,
96]. Thus, according to several studies on human and on
mouse models, CD105+CSCs, identified in RCC, might orig-
inate from transformed CD105+ bone marrow-derived MSCs
[97–101] or mesenchymal/stromal cells [102], rather than
from the kidney itself. In particular, generation of RCC of
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human recipient cell origin arising in the grafted kidney was
reported, suggesting the integration in the grafted kidney of
circulating cells originating in the recipient and their subse-
quent transformation in the graft [100]. Moreover, in vitro and
in vivo multipotent differentiation of CD105+ TICs is consis-
tent with the ability of mutated bone marrow MSCs to gener-
ate both tumor and tumor vasculature cells [103]. Additional-
ly, mesenchymal cells, present in the tumor stromal microen-
vironment, supposedly undergo neoplastic mutations, epige-
netic changes or chromosomal aberrations [104–106]. In con-
trast to cells forming mesenchymal tumors, renal CD105+
TICs expressed Pax-2 and were able to generate in vivo seri-
ally transplantable tumors being epithelial cancers
(carcinomas) as a tumor of origin. Within those tumors, they
gave rise to the CD105+ undifferentiated, tumorigenic popu-
lation and CD105− non-tumorigenic differentiated cells, and
did not differentiate into adipocytes and osteocytes [47].
In conclusion, the source of the most specifically described
putative renal CD105+CSCs [47, 54, 55], but also of other
RCC TICs (see Table 1), may be diverse, not necessarily in-
volving kidney-resident MSCs (see Fig. 1). A common CSC
marker, CD133, is probably not associated with renal TICs
[33, 47, 56, 58, 61, 82, 83], however, some findings contradict
this statement [84–86]. Thus, further studies are necessary to
eliminate all inconsistencies (Figs. 2 and 3).
Hypoxia in RCC Progression
Molecular Regulation of Cell Response to Hypoxia
Tissue hypoxia is defined as reduced oxygen partial pressure≤
2 % (≤15 mm Hg). Most mammalian tissues exist naturally at
2–9 % O2 (on average 5.5 %, 40 mm Hg) [107], including
renal cortex with proximal and distal tubules (7 %, 50 mm
Hg). In contrast, the kidney medulla is physiologically poorly
oxygenated (1.4–2.8 %, 10–20 mm Hg) [108]. Heteroge-
neously distributed areas with insufficient blood supply may
develop within rapidly growing solid tumors and their metas-
tases. Two types of intra-tumor hypoxia are distinguished –
chronic (diffusion-limited, in tumor regions distant from
blood vessels) and acute (perfusion-limited, during blood
vessel occlusion) [109–111]. Hypoxia compromises cell biol-
ogy due to impaired energy requiring processes [107]. Cancer
cells can survive sustained oxygen deficiency as a result of a
coordinated set of adaptive cellular responses to hypoxic
stress which are complex processes involving large molecular
networks centrally governed by HIFs – HIF-1 and HIF-2 –
master regulators of oxygen homeostasis within cells. HIFs
are heterodimers composed of an unstable HIF-α (HIF-1α
or HIF-2α) subunit, tightly regulated by oxygen (hypoxia-
sensitive), and a stable, constitutively expressed (regardless
of oxygen level) HIF-β subunit, also known as ARNT [107,
112–117].
pVHL, through its oxygen-dependent posttranslational
polyubiquitination of HIF-1α/2α subunits, plays a central role
in the mammalian oxygen-sensing pathway [115]. The VHL
gene was isolated in 1993 [118] and mapped to 3p25–p26.
The gene sequence is highly conserved in primates and ro-
dents, and has homologues in Caenorhabditis elegans and
Drosophila melanogaster. Sequence conservation is particu-
larly high across regions known to be involved in pVHL bind-
ing to other proteins [119]. pVHL binds to elongin C which
forms a multi-subunit complex with elongin B and Cul2/Rbx1
proteins having E3 ubiquitin ligase activity, thus, pVHL is
proposed to act as the substrate recognition subunit of this
complex recruiting HIF-1α/2α for polyubiquitination
resulting in their subsequent 26S proteasome-mediated degra-
dation. The hydroxylation of evolutionarily conserved two
proline residues of HIF-α under sufficient oxygen tensions,
carried out by members of the EglN prolyl hydroxylase fam-
ily, also known as PHDs, creates high affinity of modified
HIF-1α/2α to the pVHL binding site [113, 120–122]. Classi-
cally, HIF-1 and HIF-2 are regulated by rapid degradation of
translated HIF-1α and HIF-2α subunits at normal oxygen
levels (normoxia) or their stabilization in hypoxia. Decreased
oxygen tensions lead to increased activity of HIF. After dimer-
ization of HIF-1α/2αwith the HIF-β subunit, constantly pres-
ent in the cell cytoplasm, HIFs in an active state translocate to
the nucleus and bind, in concert with co-activators p300 and
CBP, to HREs located in promoters of their hundreds of down-
stream target hypoxia-inducible genes which become tran-
scriptionally activated [107, 112, 116, 117, 123–125]. Ap-
proximately 1–1.5 % of the human genes are regulated by
HIFs [126]. A less studied HIF-3α subunit shares a DNA-
binding domain with HIF-1α/2α subunits, but lacks a tran-
scription activation domain. Therefore, HIF-3α is considered
to serve as a dominant negative regulator of HIF-1α/2α-me-
diated transcription by the inhibition of the binding of HIF-α
subunits to promoters of their target genes [127].
ccRCC Pathogenesis – Effect of Unique Pseudo-hypoxic
Phenotype Due to a Tumor-suppressor pVHL Loss
of Function
The genomic 3p25 region, carrying the VHL gene, is com-
monly deleted or altered in ccRCC [128]. The VHL gene has
a critical gatekeeper role in the regulation of growth and dif-
ferentiation of renal tubular cells. It acts as a classic two-hit
TSG [119], as defined by Knudson [129]. The loss of normal
TSG function due to its biallelic inactivation in renal epitheli-
um may initiate cancer development. As the hits, the genome
of ccRCC cells generally shows deletion, mutation and meth-
ylation within both maternal and paternal loci of the VHL
gene, in accordance with its role as a TSG [122]. A biallelic
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loss of function of the VHL gene occurs in the majority of
sporadic and in all heritable (familial) ccRCC cases [115,
122]. This inactivation is believed to be one of the earliest
stages of renal tubular cell neoplastic transformation to
ccRCC, as it is observed in pre-malignant cystic lesions of
the kidney as well as in advanced tumors [122]. A functional
loss of the VHL gene usually occurs in ccRCC [115, 122]. The
restoration of VHL gene function in VHL −/− ccRCC cells is
sufficient to prevent them from growing as tumors in vivo
[130]. In the setting of sporadic ccRCCs, both a first and a
second hit occur somatically. Thus, they are confined only to
somatic cells of an individual, therefore, are not heritable
[122]. Somatic mutations of one allele (maternal or paternal)
of the VHL gene were observed in 42–71 % of sporadic
ccRCC cases, accompanied by deletion of the second gene
copy, manifested as LOH on chromosome 3p25–p26, in 73–
98% of those lesions. These mutations were heterogeneous in
type and distributed across much of the gene [131–135]. A
copy of the VHL gene can also be epigenetically inactivated
(silenced) by hypermethylation of normally unmethylated
CpG in the 5′ region (promoter) of the VHL gene in about
20 % of sporadic ccRCCs [135, 136]. The absolute majority
of those ccRCC cases show methylation of one allele of the
VHL gene and subsequent deletion of the other (LOH). Thus,
DNA methylation may represent another mechanism of the
VHL gene biallelic inactivation which seems to function iden-
tically to inactivating somatic mutations of its one allele in
association with a loss of the second allele. Occasionally, both
retained alleles are methylated. This methylation phenomenon
was detected for a number of TSGs [136]. A loss of normal
VHL gene function is also common in familial ccRCC asso-
ciated with rare autosomal dominant VHL disease [116, 119].
Individuals with the VHL disease carry in their germline one
VHL allele inactivated through mutation (a first hit) and one
Fig. 1 The CSC model in RCC.
a. A general hierarchical model of
tumor heterogeneity. b.
Hypothetical cells of origin of
putative renal CD105+ TICs.
CD105+ cells are the first and
most thoroughly studied renal
CSC population identified by now
[47]. The most probable cell of
origin seems to be a resident renal
adult multipotent CD105+ stem
cell retaining mesenchymal
phenotype (a MSC), possibly that
studied by Bruno et al. [76]
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Fig. 3 A hypothetical HIF-1α/
2α-dependent signaling crosstalk
within putative renal CSCs
involving pathways of three
associated markers: CD105,
CXCR-4 and ALDH. As a
presumable oncogene, HIF-2α is
supposed to drive progression of
pVHL-defective, pseudo-hypoxic
ccRCC (the absolute majority of
clinical cases), possibly including
promotion of aggressive,
immature CSC-like phenotype.
The figure does not represent
pathways in a particular putative
renal CSC population, but serves
as the summary model of all
known interactions in various




Fig. 2 A putative connection between hypoxia and immature CSC-like phenotype in RCC
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wild-type allele [115]. Pathological changes ensue when the
wild-type allele is deleted or somatically inactivated due to
hypermethylation or mutation (a second hit). In an individual
with a germline mutation in one allele of the VHL gene, the
probability of a second hit occurring somatically in the wild-
type allele is much higher than the probability of two indepen-
dent somatic hits in a normal individual. This fact explains
why ccRCC in VHL patients often develops at earlier age than
equivalent sporadic tumors in general population [122].
In ccRCC cells, lack of functional pVHL due to a VHL
gene loss of function through the biallelic inactivation pre-
vents from HIF-1α and HIF-2α polyubiquitination and sub-
sequent proteasome-mediated degradation, even under
normoxic conditions, allowing them to increasingly accumu-
late and form stable HIF-1/2 heterodimers, what results in
their pathological constitutive activation. This unique intra-
cellular pseudo-hypoxic phenotype, present as an intrinsic tu-
mor feature, mimics intra-tumor hypoxia [2, 137, 138], con-
tributing to dramatic phenotypic shift in expression of HIF
target genes promoting tumor aggressiveness, including an-
giogenesis, proliferation/mitogenesis, survival/resistance to
apoptosis, increased invasiveness and metastatic potential,
glycolytic metabolism and extracellular acidosis, hence, deter-
mining a poor outcome [107, 111, 112, 117, 125, 139–142].
Hypoxia Effect onCSC-Like Phenotype in RCC –General
and Specific Evidence
CSC-Related Pathways
CSC-associated genes are also being considered HIF-target.
Both long-standing and emerging data show an effect of hyp-
oxia on the maintenance of normal embryonic and multiple
adult stem cell populations [26, 27, 29, 143–147]. The reason
why hypoxia stimulates stem cell maintenance is largely un-
known, but one attractive hypothesis assumes stem cell local-
ization in the low oxygen microenvironment to reduce DNA
damage resulting from ROS-associated genotoxic oxidative
stress [29, 148]. Most colon CD133+CSCs are located in
hypoxic niche protecting them from chemotherapy [149].
CSCswithin several brain tumors preferentially locate in hyp-
oxic [150, 151] or pseudo-hypoxic (HIF-2α) perivascular
(oxygenated) niche [151–155]. Hypoxia promotes self-
renewal capability and inhibits differentiation of glioma/
glioblastoma CSCs [154–156]. Glioma CSCs, cultured in the
presence of oxygen partial pressure lower than 2 %, display
less spontaneous differentiation than when cultured in 21 %
oxygen [154]. Reduction in oxygen tension in spheroid cell
cultures established from glioma dramatically increases the
percentage of cells expressing the CD133 CSC marker [155,
157], but also enhances their stem cell-like phenotype (Oct4,
Sox2 and Nestin expression) [155]. HIF-2α is believed to play
a central role in CSC maintenance in hypoxia. Compared to
HIF-1α, which is expressed both in glioma/glioblastoma
CSCs and non-stem cancer cells in hypoxia, HIF-2α has a
unique expression pattern – it is highly induced only in CSCs
[154, 158]. In this line, HIF-2α overexpression in glioblasto-
ma cells promotes CSC-like phenotype and significantly in-
creases tumorigenicity [158]. However, both HIF-1α/2αwere
shown to be critical for CSC maintenance, as the knockdown
of either HIF-1α or HIF-2α reduced self-renewal capacity,
enhanced differentiation, attenuated tumorigenicity and in-
creased apoptosis of glioma/glioblastoma and neuroblastoma
TICs, resulting in less aggressive tumor phenotype [153, 154,
156, 158]. Interestingly, HIF-2α is not expressed in normal
neural stem cells, making it a very attractive target for CSC
drug development [154].
Hypoxia was shown to modulate critical, specific signaling
pathways, that control the capacity for self-renewal,
multipotency/differentiation and proliferation of CSCs. Mo-
lecular links between HIFs and these key regulatory factors
confirm the emerging concept that HIFs not only act in met-
abolic adaptations of cancer cells, but can also control their
immature phenotype. A broad spectrum of activities, influ-
enced by HIFs, overlaps with pathways affected by c-Myc, a
crucial oncogenic transcription factor. These interactions can
influence tumorigenesis of several cancers [159], including
ccRCC. In this tumor, HIF-1α/2α appear to have contrary
effects on c-Myc. Whereas HIF-1α counteracts c-Myc path-
ways in cell cycle arrest (proliferation inhibition) of pVHL-
deficient, pseudo-hypoxic ccRCC [160] as well as of colon
carcinoma [161], HIF-2α promotes c-Myc activity in pVHL
−/− ccRCC [160]. HIF-dependent effects on c-Myc can be
used to classify pVHL-defective ccRCC into two subtypes –
HIF-2α-expressing subtype (displaying increased c-Myc ac-
tivity and faster proliferation) and HIF-1α/2α-expressing sub-
type (displaying neither enhanced nor diminished c-Myc ac-
tivity due to HIF-1α/2α antagonism) [162]. Analogous to c-
Myc, while HIF-1α promotes p53 phosphorylation and sub-
sequent p53-induced apoptosis upon γ-radiation, HIF-2α in-
hibits them, leading to overall reduction of p53 activity under
radiation resulting in radioresistance (a significant feature of
CSCs). From the clinical point of view, similarly to interac-
tions of HIFs with c-Myc, the ccRCC subtype that expresses
the HIF-2α has markedly less phospho-p53 (and develops
radioresistance) compared to ccRCC subtype expressing both
HIF-1α/2α [163]. To sum up, antagonistic effects of HIF-1α/
2α towards c-Myc and p53 appear to influence ccRCC devel-
opment and progression. In view of CSCs, this phenomenon
has a great clinical significance pointing to HIF-2α oncogenic
function in ccRCC. Another stem cell factor, Oct4, was dem-
onstrated to maintain hypoxic tumor cells in an undifferenti-
ated state towards enhanced progression [164]. As c-Myc
[160] and Oct4 [164] activation is HIF-2α-dependent, hypox-
ic regulation of these two stem cell factors may powerfully
impact CSC formation from cells expressing HIF-2α.
930 Stem Cell Rev and Rep (2015) 11:919–943
Moreover, Oct-4 and c-Myc, along with Sox2 and Klf4, are
required for the formation of iPSCs from adult fibroblasts
[165], and that hypoxia enhances the generation of iPSCs
[166]. In numerous cancer cell lines, including RCC cell lines,
HIFs were demonstrated to induce expression of all iPSC-
related markers as well as of Nanog embryonic stem cell
marker [167]. Like c-Myc and Oct4, Sox2, Klf4 and Nanog
are HIF-2α-dependent [168]. The ability of the hypoxic mi-
croenvironment to potentiate the Notch pathway in lung ade-
nocarcinoma [169], malignant melanoma [170] as well as gli-
oma CSCs [171] was documented. Notch is a HIF-1α-target
[172], however, recent evidence also indicates a regulative
role of HIF-2α as signaling repressor [171]. In addition,
Wnt/β-catenin signaling governs CSC features in response
to hypoxia [173]. In ESCs, this pathway was shown to be a
HIF-1α-target [174]. The opposite result was reported for co-
lon carcinoma cells in which HIF-1α inhibited Wnt/β-catenin
activity [175]. Thus, it can be suggested that the interaction
between HIF-1α and Wnt/β-catenin is functionally distinct in
various cell types. Finally, proteins regulating other crucial
stem cell functions have been identified as HIF-targets. A
gene encoding glycoprotein ABC-Ts, MDR1, which confers
multidrug resistance on a variety of cancer cells, is a direct
HIF-1α-target [176]. In addition, hTERT, a gene encoding the
enzymatic component of human telomerase that promotes im-
mortalization of CSCs, is induced by hypoxia in a HIF-1α
dependent manner [177]. Hypoxia (HIF-1α) may also en-
hance genetic instability of CSCs, favoring their undifferenti-
ated state [143]. Furthermore, SCD1, an enzyme in the bio-
synthesis of monounsaturated fatty acids from saturated fatty
acids, is upregulated under hypoxia and modulated byHIF-2α
in ccRCC. Upregulation of SCD1 in response to HIF-2α en-
hanced HIF-2α expression in a positive feedback loop medi-
ated by Akt pathway [178]. Indeed, the Akt-downstream pro-
tein, mTOR, can directly activate not only HIF-1α [142], but
also HIF-2α [179]. Synergistic effects between SCD1 and
HIF-2α contributed to tumor progression: survival (apoptosis
inhibition), colony formation ability and migration capacity
(metastasis) of pVHL −/− 786-O cells. Once pVHL was re-
stored, SCD1 expression became less sensitive to changes in
HIF-2α level [178]. SCD1 is also a key factor for lung
spheroid-forming TICs. SCD1 upregulation in lung cancer
spheroids is parallel with increased ALDH CSCmarker activ-
ity [180] that was found to be associated with some renal TIC
populations [70–72]. It was shown that increased ALDH ac-
tivity promotesCSC-like phenotype of breast cancer through a
novel mechanism involving HIF-2α upregulation [181,
182]. Inhibition of ALDH suppressed CSC properties both
in vitro and in vivo [181]. Importantly, the only study
analyzing the influence of hypoxia on putative CSCs in
RCC was performed on one of identified ALDH+ popula-
tion associated with SP cells (derived from pVHL +/+
ACHN cell line). Hypoxic treatment incresed the number
of ALDH+ cells 2–3 times; however, more detailed studies
were not done [72].
De-differentiation/EMT
Beyond evidence for the maintenance of the CSC-like poten-
tial, hypoxia was indicated to directly alter gene expression of
non-stem cell-like neoplastic cells, promoting their spontane-
ous de-differentiation towards immature stem cell-like pheno-
type in neuroblastoma [183], breast carcinoma [184], glio-
blastoma [158], ovarian cancer [185] and osteosarcoma cell
lines [186]. De-differentiated malignant cells acquired CSC-
like properties, including self-renewal ability [158, 185, 186],
multipotency [186], tumorigenicity [158, 183, 186],
invasiveness/metastatic potential [183–186] as well as expres-
sion of essential stem cell factors: Notch in neuroblastoma
[183], Oct4, c-Myc and Nanog in glioblastoma [158], Oct4
and Sox2 in ovarian cancer [185], and Oct4 Sox2 and Nanog
in osteosarcoma studies [186]. In ductal breast carcinoma in
situ, tumor cells were less differentiated in hypoxic areas of a
malignant lesion, confirming results of de-differentiation ex-
periments on breast carcinoma cell lines [184]. In agreement
with these studies, malignant melanoma cell lines may acquire
CSC-like phenotype through Oct4-mediated cell de-
differentiation [187]. There is a strong correlation between
tumor clinical stage, differentiation status and behavior. High
stage cancers are mostly immature (poorly differentiated)
which makes them more aggressive than their more differen-
tiated counterparts [188]. Hypoxia-induced cell de-
differentiation contributes to cancer cell plasticity and hetero-
geneity, hence, has a direct clinical impact. This appears to be
a general phenomenon in solid tumors and the mechanism to
explain their increased aggressiveness and unfavorable out-
come [189].
Molecular mechanisms ruling tumor cell de-differentiation
came into focus along with the CSC concept. It is noticeable
that terms de-differentiation and EMT show a considerable
degree of conceptual overlap. EMT describes how epithelial
cancer cells de-differentiate towards mesenchymal,
fibroblastoid, spindle-shaped, apolar cells, simultaneously
gaining increased motility and invasiveness [188]. EMT en-
dows transitioned cancer cells with stem cell-like properties,
providing a mechanistic link between mesenchymal pheno-
type, CSCs, metastatic potential and resistance to therapies
[94, 126, 190–195]. An important question in this context is
to what degree EMT equates to de-differentiation [188]. A set
of diverse extracellular stromal (microenvironmental) signals
was reported to induce EMT in malignant epithelial cells,
includingWnt/β-catenin and Notch stem cell markers, growth
factors such as TGF-β, EGF, FGF and PDGF, transcription
factors such as TWIST, SNAIL and ZEB, inflammation cyto-
kines such as tumor necrosis factor-α (TNF-α) and interleu-
kins as well as other specific molecules [191, 194–196]. EMT-
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triggering mechanisms in cancer are activated by hypoxia [25,
126, 190, 191, 195, 196]. Also hypoxia-responsive EPO,
overexpressed especially in ccRCC, might stimulate EMT
mediated by PI3K/Akt/mTOR pathway [197].
In pVHL-defective, pseudo-hypoxic ccRCC cells, HIF-1α
deregulation was linked to the downregulation of E-cadherin
and induction of EMT [198–203] – a second specific hallmark
of RCC (beyond abundant angiogenesis) [142]. In addition,
hypoxia occurring after renal injury may activate a de-
differentiation program in tubular epithelial cells through
Oct4 induction providing mesenchymal CD133+ progenitor
phenotype whichmay contribute to kidney regeneration. Hyp-
oxia contributes to increased clonogenicity, proliferation and
VEGF synthesis by renal medullary progenitors. These effects
are reduced by HIF-1α downregulation and followed by pro-
genitor epithelial differentiation [41]. Indeed, CD133 expres-
sion is strongly related to the nuclear HIF-1α protein within
786-O RCC cell line and may be upregulated under hypoxic
environment [204]. Importantly, with regard to the first and
most accurately described population of putative renal CSCs,
CD105+ cells [47], given the endoglin role in activated endo-
thelial cells [44–46], it is not surprising that there is a positive
correlation between hypoxia and CD105 protein expression –
it is a HIF-1α-target [205]. CD105, along with TβRII and
ALK, is a part (a co-receptor) of TGF-β1 receptor complex
[44–46, 205, 206]. The complex is characterized by serine-
threonine kinase activity [206]. Via MAPK/ERK pathway,
which is Smad-independent, TGF-β1 is supposed to crosstalk
with Wnt, Notch, IGF and PDGF signaling in order to induce
de-differentiation/EMT in osteosarcoma cells. TGF-β1 ex-
pression might be activated in the MAPK/ERK-dependent
autocrine loop to further promote de-differentiation [186].
Moreover, TGF-β1-EMT axis (Smad-dependent) through
TβRII is supposed to play an important role in the in vitro
induction of one of sphere-forming CSC-like populations in
RCC and in associated in vivo sarcomatoid de-differentiation
within xenografts derived from these tumor spheres [59]. In
line with the activation of TGF-β signaling, endoglin en-
hances the invasiveness of brain metastatic breast tumor cells
by induction of MMPs (involved in metastasis) and chemo-
taxis to TGF-β frommetastatic site [207]. Ewing sarcoma and
melanoma research indicates that CD105 can also contribute
to tumor aggressiveness independently from TGF-β (inhibi-
tion). Endoglin acts in concert with FAK and PI3K signaling
to maintain in vitro plastic phenotype and invasiveness (colo-
ny- and spheroid-forming ability) as well as in vitro and
in vivo growth of tumor cells, which result in poor prognosis
[208]. FAK determines tumor aggressiveness by both the in-
duction of matrix MMPs (via PI3K/Akt/mTOR pathway) and
EMT [209]. Tumor cell plasticity is an alternative mechanism
of tumor blood perfusion to complement the endothelial cell-
dependent vasculature. It implies the possibility that some
high-grade tumor cells display multipotent embryonic stem
cell-like phenotype which enables their differentiation to-
wards abnormal endothelial-like cells forming de novo
ECM-rich vascular-like channels. This pseudo-tubular struc-
tures mimic the pattern of embryonic vascular network, thus,
is called VM [208, 210]. The VM phenomenon is induced by
hypoxia [208]. The characteristics of undifferentiated cells
underlying VM is not well understood [210]. Alternatively, a
link between EMT, CSCs and VM was proposed. Because
tubular-like cells show a significant expression of both endo-
thelial and immature tumor phenotype, VMmay represent the
transitory step in incompleteCSC differentiation into endothe-
lial cells [211, 212]. Indeed, the in vivo ability for endothelial
differentiation of CD105+ RCC CSCs and the consequent in-
volvement in tumor vascularization were described [47]. The
presence of CSC-dependent vasculogenesis in RCC explains
altered embryonic phenotype and behavior of derived endo-
thelial cells such as chromosomal abnormalities and the inde-
pendence on growth factor supply [212]. In addition, VMwas
found in xenografts arisen from CSC-like spheres of RCC.
However, as mentioned above, TGF-β1 signaling, potentially
blocked by CD105, plays an important role in the governance
of this CSC population. Nevertheless, it is unknown if these
cells express CD105 [59]. In RCC, VM is an independent
unfavorable prognostic factor [213]. In a few studies, in con-
trast, CD105 was shown to be a tumor repressor by the inhi-
bition of TGF-β signaling [208, 214]. Thus, it is presumed
that endoglin function is context-dependent, and TGF-β sig-
naling is highly complex [208]. Finally, another putative renal
TIC marker, CXCR-4, is upregulated by HIF-1α in pVHL-
defective ccRCC [82, 215, 216]. SDF-1α-CXCR-4 axis can
activate EMT/metastasis of CSCs [25].
It should be emphasized that intrinsic pVHL-deficient
pseudo-hypoxic phenotype is not the common basis of can-
cer, except the absolute majority of ccRCC clinical cases.
Somatic mutations of the VHL gene are extremely rare in
epithelial solid tumors (including the minority of RCC clin-
ical cases). These pVHL-wild-type tumors often contain
chronic and acute hypoxic regions acquired during devel-
opment. In these regions, active HIF-α subunits accumulate
owing to their impaired hydroxylation (lack of oxygen) and
can affect tumor cell behavior [142]. HIFs appear to be
regulated appropriately within pVHL +/+ RCC cells, mean-
ing that they can respond to hypoxia [124], as in the case
of identified putative renal ALDH+ ACHN CSCs induced
by hypoxic treatment [72]. However, it is unknown, what
specifically initiates pVHL-wild-type ccRCC [124].
Mathieu et al. [167] showed that both 786-O pVHL −/−
cells, cultured in normoxia, as well as pVHL +/+ cells,
cultured in 2 % hypoxia, expressed similar levels of Oct4,
Sox2 and Nanog markers. The question is, what happens
within putative pVHL −/− pseudo-hypoxic renal CSCs
when acute/chronic hypoxia starts to develop within a tu-
mor? Might pseudo-hypoxic HIF overproduction increase
932 Stem Cell Rev and Rep (2015) 11:919–943
or has it already reached the limit and the number of in-
duced CSCs remains at the same level?
Taken together, above-mentioned findings indicate that
hypoxia rules immature cancer cell phenotype being an im-
portant aspect of the tumor microenvironment which, along
with other niche components (such as growth factors), plays a
fundamental role in conferring higher aggressiveness to tumor
cells. It can be assumed that stem and non-stem cell-like pop-
ulations exist in a dynamic equilibrium within a solid tumor.
Therefore, hierarchical models of CSCs should be considered
to serve as a microenvironment-stimulated interconversion
between immature and mature tumor cell components [186].
Hypoxia alters expression level of hundreds of genes and, as a
consequence, it is unlikely that a single mechanism can ex-
plain cell de-differentiation towards CSC-like phenotype in-
duced by reduced oxygen tension. The combined effect of
HIF-overactivation may ultimately impose attributes of stem
cell identity on more differentiated transformed cells. Howev-
er, it should be emphasized that this outcome would likely be a
rare event – only these hypoxic cells which express a partic-
ular level of relevant stem cell factors would be expected to
gain CSC characteristics [29]. Moreover, it is apparent from
current literature that a fraction of cancer cells expressing spe-
cific surface marker(s) varies widely between tumors from
less than 1 % to upwards of 25 %, but it remains uncertain
whether these numbers reflect a true proportion of CSCs and/
or all marker-positive cells possessCSC-like phenotype [126].
HIF-2α as a RCC Oncogene
It is currently unknown why VHL gene inactivation is only
linked to ccRCC, although both pVHL and HIFs are
expressed in the majority of human cells [124]. It was ob-
served, though, that the medulla of the mammalian kidney is
hypoxic in normal physiological conditions [108]. Moreover,
among various epithelia tested, renal epithelial cells seem to
be particularly sensitive to mitogenic effects of HIF-
responsive TGF-α [217, 218]. In addition, hypoxia causes
the upregulation of cyclin D1 via HIF activation, stimulating
cell proliferation of the renal epithelium, as opposed to other
tissues [219–221]. Finally, some differences in proliferation
rate between renal and other epithelial cell types have been
observed. Intriguingly, epigenetic differences between cells
within the kidney and other organs allow the renal epithelium
to proliferate under reduced oxygen levels. Thus, it may be
concluded that renal epithelial cells, proliferating in hypoxia,
are more susceptible to oncogenic effects of the pVHL
loss/HIF activation [124]. Other altered genes, which cooper-
ate with the VHL gene loss of function to initiate tumor devel-
opment, should also be identified [115]. Moreover, whether
pVHL has any tumor-suppressor functions unrelated to its
ability to inhibit HIFs needs to be understood, particularly in
view of such pVHL functions as the regulation of ECM for-
mation and turnover, and the modulation of cell death [142].
While both HIF-α subunits show significant homology,
most studies were focused on HIF-1α due to its earlier dis-
covery and more universal expression patterns within mam-
malian tissues than HIF-2α, as HIF-2α expression is restricted
to particular cell types, including interstitial cells of the kidney
[26, 29]. The role of HIF signaling during kidney develop-
ment is unclear, but cell type- and stage-specific expression of
HIF-1α/2α correlates with expression of critical angiogenic
factors such as VEGF and CD105. Although HIF-1α/2α seem
to activate hypoxia-responsive genes by similar means, they
are non-redundant and regulate both overlapping and unique
downstream target genes [138]. HIF-1α/2αwere proven to be
differently regulated in a number of tumors and seem to have a
different impact on tumor behavior and patient outcome in
neuroblastoma [222, 223], glioma/glioblastoma [154, 158]
as well as breast [224] and non-small cell lung carcinoma
[225, 226]. HIF-1α was postulated to be involved in cell ad-
aptation to acute hypoxia, whereas HIF-2α to chronic hypoxia
[222, 224]. Different expression patterns and roles of HIF-1α/
2α in various tumors indicate the importance of their specific-
ity for cancer survival and propagation [28]. With notable
exceptions, HIF-1α itself generally functions as an oncogene
in a number of solid tumors, including breast, colon and brain
cancer [107, 227], and its levels are informative negative prog-
nostic factors for many malignancies, correlating with worse
outcome [111, 228]. In pVHL −/− ccRCC, in contrast, HIF-1α
appears to act as a tumor-suppressor [229]. In turn, HIF-2α
was supported as a tumor-suppressor in neuroblastoma, de-
spite its promotion of angiogenesis [230]. However, a number
of studies indicate that HIF-2α may possibly function as an
oncogene, but only in specific tumor types, in certain molec-
ular contexts [152, 224, 225, 231, 232], also in RCC. Several
findings on ccRCC show a particularly important role of HIF-
2α deregulation in pVHL-deficient pseudo-hypoxic renal car-
cinogenesis, proving that HIF-2α, not HIF-1α, is an onco-
gene, at least in the setting of this type of RCC:
1. HIF-1α signaling pathways are activated early in devel-
opment of VHL disease-associated pre-neoplastic kidney
lesions, while HIF-2α is detected in more advanced le-
sions. The apparent switch from HIF-1α to HIF-2α accu-
mulation in more advanced lesions coincide with in-
creased kidney dysplasia [233]. HIF-2α expression is vi-
tal for ccRCC development in a mouse model [234].
2. ccRCC pVHL −/− cell lines express either both HIF-1α
and HIF-2α, or HIF-2α alone, suggesting that there may
be selection pressure to maintain HIF-2α expression or
lose HIF-1α expression [121].
3. HIF-2α variants lacking prolyl hydroxylation sites can
override tumor suppression by pVHL in animal models,
whereas analogous HIF-1α mutants cannot, indicating
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that HIF-2α inhibition is necessary for pVHL-dependent
tumor suppression [234–238].
4. HIF-2α overexpression in ccRCC cell lines expressing
functional pVHL results in enhanced xenograft tumor
growth [234, 235, 238], in contrast to HIF-1α which in-
hibits ccRCC growth [237, 238]. Moreover, HIF-2α pro-
motes (and HIF-1α inhibits) pVHL-deficient ccRCC pro-
liferation in vitro via c-Myc signaling [160] and its radia-
tion resistance via phosphorylation inhibition of p53
[163].
5. The elimination of HIF-2α through its siRNA-mediated
downregulation is sufficient to suppress the in vivo tumor
growth of pVHL-defective ccRCC cells [235, 239].
6. Despite the fact that both HIF-α isoforms target the same
HREs during renal carcinogenesis, expression of genes
involved in the glycolytic pathway is driven preferentially
by HIF-1α [240], whereas in pVHL-defective ccRCC
cells, HIF-2α preferentially promotes tumor growth and
angiogenesis – it induces expression of cyclin D1, TGF-α
and VEGF, which may be understood in the light of HIF-
2α being activated mainly during late ccRCC progres-
sion, in advanced lesions. However, in pVHL-competent
RCC cells and non-RCC cells, cyclin D1, TGF-α and
VEGF appear to be potentially responsive to both HIF-α
isoforms [238].
Conclusions, Therapeutic Implications and Future
Directions
CSCs do not necessarily arise from altered normal stem cells,
as they could also originate from normal differentiated cells
that acquired self-renewal ability and became malignant [4,
35]. CSCs in some tumors may actually not be static and well
defined, but rather display dynamic stemness properties de-
pending on the microenvironmental context [186]. In line with
this, putative TIC populations, identified in RCC, display di-
verse phenotypes/markers [47, 56–59, 61, 65–67, 70–72], as
CSCs of malignant melanoma [23] as well as colorectal [16]
and ovarian cancer [21]. Because CSCmodel in RCC is main-
ly based on functional approaches due to lack of generally
applicable markers, it is important to optimize isolation and
characterization methods of kidney-specific stem/progenitor
cells to potentially rule them out as cells of TIC origin [3].
Currently, intensive attention is focused on the hypoxic mi-
croenvironment as a central mechanism governing CSCs
[25–29] and related EMT/de-differentiation [25, 126, 190,
191, 195, 196] which, in turn, are being increasingly recog-
nized as the goal to cure cancer. HIF signaling pathways have
been studied in the last few years as extremely attractive tar-
gets of therapeutic intervention [117, 140, 241, 242]. Reduc-
tion of HIF activity in CSCsmay promote their differentiation
[29]; on the other hand, disturbance of theCSC nichemay also
lead to loss of stemness characteristics [243] – both ap-
proaches might decrease tumor growth, improve its response
to chemo- and radiotherapy, and diminish the ability to re-
lapse. Despite the explosion of information on hypoxia in
RCC progression, there are still major questions to be ad-
dressed in the field of the dependence of putative renal CSCs
from their HIF signaling, especially oncogenic HIF-2α.
In light of strong RCC resistance to chemo- and radiother-
apy, and its high metastatic index, the identification of cells
which are responsible for RCC development and mainte-
nance, coupled with deep knowledge about their biomarkers,
intra-cellular pathways and genetic abnormalities, may lead to
efficient therapeutic strategies targeting this aggressive popu-
lation by elimination and/or differentiation in various patient
subtypes within different treatment responses and disease
stages [3, 244]. A comprehensive molecular analysis of
RCC [6, 245, 246] and pharmacogenomics of putative CSCs
[247] are necessary for development of personalized treatment
strategies. Epithelial differentiation of renal CD105+ TICs was
tested – IL-15 was proposed as an interesting drug candidate
[248]. Previous studies provide the rationale for this approach.
First, IL-15 was shown in murine studies to be an autocrine
survival factor for renal tubular epithelial cells. In addition,
in vitro studies indicated that IL-15 upregulates expression
of E-cadherin on human renal tubular epithelial cells and in-
hibits their EMT. Therefore, IL-15 is suggested to act as the
sensor of normal tubular homeostasis. It can be speculated that
a loss of intra-tumoral secretion of IL-15 by RCC might be a
stemness protection mechanism of CD105+ cells [3]. After IL-
15 treatment, renal CD105+CSCs lacked stem cell markers,
expressed epithelial markers and displayed the functional ep-
ithelial property of cell polarity. Epithelial differentiated renal
CSCs were unable to self-renew, non-tumorigenic and drug-
sensitive as well as acquired IL-15 secretion guaranteeing a
permanent epithelial differentiation state through autocrine
loops [248]. A phase I study of intravenous recombinant hu-
man IL-15 for the treatment of metastatic RCCwas completed
in February 2014 (NCT01021059). Another two phase I stud-
ies of subcutaneous IL-15 are ongoing (NCT01727076 and
NCT02452268). Moreover, endoglin downregulation in epi-
thelial ovarian cancer promoted apoptosis, induced significant
DNA damage through modulation of numerous DNA repair
genes, and improved platinum sensitivity both in vitro and
in vivo, which implies that anti-CD105 therapy would allow
dual treatment of both tumor angiogenesis and a subset of
aggressive, chemoresistant CD105+ tumor cells [249]. A num-
ber of strategies to inhibit or downregulate (RNAi) another
putative renal CSC marker, CXCR-4, have recently been pro-
posed and are undergoing clinical trials [244]. In particular,
downregulation of CXCR-4 using siRNA as well as its phar-
macological inhibition by AMD3100 (Plerixafor) contributed
to sphere formation blockade of CXCR-4+ RCC CSCs, and
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increased their responsiveness towards anti-angiogenic agents
Sunitinib, Sorafenib and Pazopanib [56]. Also, the DNAJB8
putative CSC marker of RCC was evaluated as an immuno-
therapeutic target in DNA vaccination experiments [57]. Fur-
thermore, honokiol, a multifunctional anti-angiogenic and
anti-tumor natural agent [250], inhibits proliferation, reverses
EMT (increase in epithelial markers) and suppresses CSC
properties of RCC cells both in vitro (invasiveness/migration,
sphere formation, SP) and in vivo (tumorigenicity) [251].
Honokiol interferes with Ras/Raf/MEK/ERK tumor-
promoting pathway [252]. In light of HIF-2α dependence of
pVHL-defective ccRCC progression, because SCD1 seems to
maintain a positive feedback loop that upregulates HIF-2α
towards enhanced tumor progression, therapy targeting both
SCD1 and HIF-2α might be effective in the treatment of
pVHL −/− ccRCC [178]. Indeed, combinatorial application
of SCD1 small molecule inhibitor, A939572, with mTOR
inhibitor, Temsirolimus, synergistically attenuated in vitro
and in vivo tumor growth in advanced/metastatic ccRCC pa-
tients [253]. In addition, in vitro studies on pVHL −/− ccRCC
cell lines indicate that Tempol, a stable nitroxide, has potential
therapeutic activity against HIF-2α [254].
The identification of the VHL gene and understanding of its
molecular signaling pathways in renal carcinogenesis played a
major role in development of novel targeted therapeutics
against metastatic RCC. All these drugs share the ability to
block HIF-VEGF-VEGFR and HIF-PDGF-PDGFR axis that
plays a significant role in tumor angiogenesis – their use may
partially reverse the effect of pVHL loss of function, leading
to tumor regression. Among currently licensed systemic
targeted agents against advanced RCC, gradually introduced
to clinical use since 2006, there are small-molecule multiple
RTK inhibitors such as Sunitinib (SUTENT, Pfizer Inc.), So-
rafenib (Nexavar, Bayer HealthCare/Onyx Pharmaceuticals),
Pazopanib (Votrient, GlaxoSmithKline) and Axitinib (Inlyta,
Pfizer); the neutralizing anti-VEGF humanized monoclonal
antibody, Bevacizumab (Avastin, Genentech), given in com-
bination with IFN-α; and inhibitors of serine-threonine
mTOR kinase complexes (mTORC1 and mTORC2),
Temsirolimus (Torisel, Pfizer) and Everolimus (Afinitor,
Novartis Pharmaceuticals) [255, 256]. mTOR is a highly con-
served kinase implicated in RCC development, as it is in-
volved in transcriptional regulation of HIF-1α [142] and
HIF-2α [179]. Novel targeted therapeutics, used in combina-
tion or sequentially, significantly improved outcomes of pa-
tients with metastatic RCC, showing higher objective re-
sponse rate and higher median progression-free survival com-
pared to reference treatment. Results from ongoing/planned
clinical trials are expected to help to shape effective RCC
future therapeutic possibilities [255, 256]. Despite therapeutic
progress, complete and durable responses are rarely noted,
necessitating chronic therapy for the majority of RCC patients
which is often associated with significant toxicity. In addition,
the response to treatment with a specific targeted drug differs
between patients, suggesting specific molecular mechanisms
promoting individual susceptibility to each agent [255]. Pa-
tients who primarily respond to anti-angiogenic targeted treat-
ment often develop acquired (adaptive, evasive) resistance
[255, 257–260]. The initial inhibition of tumor growth and
prolongation of progression-free survival due to anti-
angiogenic therapy are associated with relapse and more in-
vasive metastatic disease [212]. Secondary intra-tumor acute
hypoxic condition following anti-angiogenic RCC therapy-
associated disruption in vasculature was proposed to promote
alternative strategies to support angiogenesis (angiogenic
switch) such as selection of tumor cell clones independent of
VEGF due to multiple molecular and/or cellular mechanisms
[255, 257]. Moreover, regarding one of identified presumable
ALDH+CSC-like populations of RCC, anti-angiogenic Soraf-
enib treatment induced a 2–3 fold increase in a number of
ALDH+ ACHN cells as compared with normal conditions
[72]. Furthermore, a study of tumorigenic CD133/CXCR-4-
co-expressing cells, contradicting a general conviction that
CD133 is not a marker of renal CSCs, showed a promoting
effect of Sunitinib-induced hypoxia in tumor perinecrotic
areas on the number of these cells, thus, Sunitinib was able
to generate resistance to its own therapeutic effect [86]. In-
deed, high CXCR-4 expression correlates with poor response
to anti-angiogenic treatment (including Sunitinib) in metasta-
tic RCC [56, 261]. In vitro studies revealed that CSC increase
in breast carcinoma xenografts due to anti-angiogenic treat-
ment (Sunitinib and Bevacizumab) followed by hypoxic con-
ditions is primarily mediated by HIF-1α (EMT induction)
[262]. In line with this, xenograft studies showed that
hypoxia-activated EMT may be responsible for RCC resis-
tance to Sunitinib [198]. Finally, induction of the VM phe-
nomenon, possibly by the switch from normal to embryonic-
like tumor vasculogenesis dependent from endothelial differ-
entiation of CSCs [211, 212] which was shown in RCC [47,
59] as well as in hypoxic conditions in breast carcinoma [53]
and leukemia [263], may also be responsible for tumor escape
from conventional anti-angiogenic therapies. However,
VEGFR inhibition by Sunitinib, but not VEGF blockade
using Bevacizumab, impaired hypoxia-induced endothelial
differentiation of renal CD105+CSCs in vitro, suggesting a
VEGF-independent mechanism [264]. Considering a strict de-
pendence of RCC on angiogenesis for tumor promotion, pu-
tative RCC CSCs may be speculated to display distinct pro-
angiogenic properties [3], especially in light of pVHL
inactivation.
In view of development of secondary hypoxia limiting the
effectiveness of current therapy, anti-angiogenic agents should
perhaps be combined with renal CSC-targeting drugs. In ad-
dition, an innovative therapeutic perspective might be the use
of hyperoxia/hyperbaric oxygen to decrease the number of
CSCs in resistant metastases (e.g., due to restoration of more
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differentiated phenotype), resensitizing them [265]. More-
over, a highly challenging issue is counteracting hypoxia-
related limitations of anti-angiogenic drugs by tumor vessel
normalization (restoration of healthy vasculature) using ITPP
[266] and a soluble form of VEGFR-2 [267] in order to inhibit
CSC selection and improve treatment efficiacy. Another prob-
lematic phenomenon for RCC therapy may be EndoMT – the
de-differentiation process of endothelial cells to invasive
CAFs which is induced by TGF-β [268]. Within the tumor
microenvironment, CAFs are supposed to cooperate to tumor
aggressiveness by the interaction with and modification of
CSCs [190]. Finally, in the context of tumor hypoxia, the wide
use of rhEPO to treat anaemia in cancer patients, especially
ccRCC, is still being discussed because of HIF-induced EPO
and EPOR overexpression. On the one hand, binding of ex-
ogenous rhEPO with EPOR might prevent or stabilize tumor
progression by decreasing hypoxia through increasing oxy-
genation (erythrocytosis). The alternative argument indicates
the possibility of rhEPO/EPOR-mediated initiation of
autocrine/paracrine pathways promoting progression [197].
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